Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
about
Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinomaNovel Immunotherapeutic Approaches for Head and Neck Squamous Cell CarcinomaNimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer PatientsMolecular targeting of glioblastoma: Drug discovery and therapiesParametric contrast-enhanced ultrasound as an early predictor of radiation-based therapeutic response for lymph node metastases of nasopharyngeal carcinoma.The emerging role of nimotuzumab in the treatment of non-small cell lung cancer.Antibody-based therapeutics to watch in 2011.EGFR inhibition prevents in vitro tumor growth of salivary adenoid cystic carcinoma.Immune biomarkers of anti-EGFR monoclonal antibody therapyRadiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.Control of advanced cancer: the road to chronicity.Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair.Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodiesProfile of nimotuzumab in the treatment of high-grade gliomaOne target, different effects: a comparison of distinct therapeutic antibodies against the same targets.A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinomaEfficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinomaNimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy.A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancerResistant metastatic penile carcinoma and response to biochemotherapy with paclitaxel and epidermal growth factor receptor monoclonal antibody, nimotuzumab.EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical EffectsTherapeutic approaches to target cancer stem cells.Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial.Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial.Optimal treatment for recurrent/metastatic head and neck cancer.Pharmacotherapy for squamous-cell carcinoma of the head and neck.Promising new molecular targeted therapies in head and neck cancer.Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities.Monoclonal antibodies as therapeutics in human malignancies.Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.Recent advances in targeted therapy for glioblastoma.Current Role of Dacomitinib in Head and Neck Cancer.Anti-EGFR Agents: Current Status, Forecasts and Future Directions.
P2860
Q26767182-B51E6404-51EF-44CA-A858-44D559E2F89BQ28071998-7D84B826-CB18-453B-8881-1C4BBA4C62D2Q33809528-4579901B-802D-4AB3-80CB-A767B77D15F3Q33911283-E70AF31C-221D-41A0-BFDD-71C3C5B26C24Q33933009-5FCA7ABD-08FD-4E67-8D28-65D0415E299BQ34343043-7CE00CA1-B7D7-43A8-8164-0A06C3493A8CQ34570079-0341ABC4-05AA-462E-8600-FC95327C2133Q34622206-99161066-3FCA-4114-8E56-4DDA80212861Q34723594-52064FAE-3110-4471-9BAF-1318F068DC99Q34778047-A5FE9546-A019-44B2-878B-5ADB32E62D74Q34874471-257C821B-BFC0-428C-8052-B4A7E2BB7567Q34970294-307E6AF3-2446-4CC6-ABEE-6D3AC335639AQ35409548-99BDCC9E-4384-4A1C-B408-65395A7F46CEQ35491503-40483CC9-776D-434B-9B44-ACC506E9D055Q35569418-BD507ACC-AAC8-4FCB-9972-79A0EA627F5DQ35667892-BCFCB1A6-DF75-4D99-99C8-7F6E91C6847BQ35948006-87611C0D-70ED-4112-A59E-5620E72C8A6BQ35955366-57347EFA-35F3-4B80-810D-566DE81BFF73Q36213066-D68D7401-CAE8-423B-A809-16AAC9B6FF76Q36303845-D080C3BD-4629-4AD6-915A-1197F257B71DQ36307227-6BA437B7-E7DE-4AB9-923C-21BA4BF9C9E7Q36425414-079DD520-B9BF-4C17-AD17-8977B0249F4FQ36656070-F300DA49-3F51-4C45-9786-53020C92074AQ37026179-12ADBC89-496D-428A-8761-F8B3E34243EBQ37132708-99618BD4-0496-421B-8AC3-863A52C5370AQ37137412-B8B905DE-3A7E-4181-A29E-29E0923BF458Q37138420-DDA20B78-6053-49C8-94EB-907C0D311479Q37269328-5BC86ECF-11A4-4847-B8F5-4D762AA75EA9Q37302618-3368C2B8-9915-411A-93C0-13336577D365Q37618803-2335F6AF-2E91-48AD-89A4-679AD7C39A75Q37709310-D9D00A7D-0BFA-42FA-9883-07C470B56146Q37799934-798BAE12-F551-487F-B05A-9A5DB9AF2000Q37831351-016FA96E-BE58-45E9-AE8E-83C0F160933DQ38084617-93765AE2-1308-4228-A7EE-00DC6A708C58Q38127413-4F2ED07D-4E26-4247-BEEC-9017E20A0B0CQ38206275-56DF4A9F-A2C6-4321-8DF7-1969AC5BA130Q38344592-8B37A0D5-621A-494C-A186-E64AA1F38E81Q38539386-D4D9B2AA-B324-46F1-8D0E-2CC9C272B142Q38806115-1CA56BE9-182C-4876-A8BE-A7D494241937Q38832105-36445D7F-68FD-4B4A-8271-68BA051E43C6
P2860
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Nimotuzumab, a promising thera ...... of tumors of epithelial origin
@ast
Nimotuzumab, a promising thera ...... of tumors of epithelial origin
@en
Nimotuzumab, a promising thera ...... of tumors of epithelial origin
@nl
type
label
Nimotuzumab, a promising thera ...... of tumors of epithelial origin
@ast
Nimotuzumab, a promising thera ...... of tumors of epithelial origin
@en
Nimotuzumab, a promising thera ...... of tumors of epithelial origin
@nl
prefLabel
Nimotuzumab, a promising thera ...... of tumors of epithelial origin
@ast
Nimotuzumab, a promising thera ...... of tumors of epithelial origin
@en
Nimotuzumab, a promising thera ...... of tumors of epithelial origin
@nl
P2093
P2860
P921
P3181
P356
P1476
Nimotuzumab, a promising thera ...... of tumors of epithelial origin
@en
P2093
A S Arvind
Anand Eswaraiah
Giselle Saurez
Harish Iyer
Melarkode S Ramakrishnan
Patricia Piedra
Tania Crombet
P2860
P3181
P356
10.4161/MABS.1.1.7509
P407
P577
2009-01-01T00:00:00Z